AG-80308 is under clinical development by Allgenesis Biotherapeutics and currently in Phase I for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase I drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AG-80308’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AG-80308 overview
AG-80308 is under development for the treatment of dry eye disease, other ocular inflammation diseases. It is administered through topical route as eye drops. It acts by targeting formyl peptide receptor 2 (FPR2).
Allgenesis Biotherapeutics overview
Allgenesis Biotherapeutics is a biopharmaceutical company that discovers, develops and commercializes innovative products for the treatment of central nervous system (CNS) and ophthalmology disorders. The company provides products pipeline such as AG-86893, a kinase inhibitor for the neovascularization of ocular surface; AG-67650, a bi-specific fusion protein targeting wet age-related macular degeneration. It offers products such as AG-12896, a disease altering small molecule for treating Alzheimer’s disease; AG-73305, a multi-specific fusion protein for the treatment of diabetic macular edema (DME), among others. Allgenesis Biotherapeutics aims at the optimization of compounds to accomplish the early clinical development of new drugs. The company provides works in alliance with National Cheng Kung University, Formosa Laboratories Inc, AP Biosciences Inc and FUJIFILM Diosynth Biotechnologies U.S.A. Inc, among others. Allgenesis Biotherapeutics is headquartered in Taipei, Taiwan.
For a complete picture of AG-80308’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
